528 results on '"Ch'ng, Sydney"'
Search Results
2. Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
4. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
5. ASO Visual Abstract: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
6. Evolution of Head and Neck Cancer Management
7. Evolution of Melanoma and Non-Melanoma Skin Cancer Management
8. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort
9. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
10. Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe
11. First Phase Development of a Patient-reported Outcome Measure for Midface Oncology
12. Local Flaps of the Head and Neck
13. New Zealand's early experience in stapled haemorrhoidopexy
14. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy
15. Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers
16. External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes
17. Fascio-cutaneous and fascio-periosteal free flaps for treatment of intermediate stage osteoradionecrosis of the jaws
18. Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?
19. Vasopressors improve outcomes in autologous free tissue transfer: A systematic review and meta-analysis
20. Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
21. Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma
22. Use of Rare Anatomical Variant of the Free Fibula Flap to Reconstruct the Nasal Septum
23. Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets
24. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).
25. Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck
26. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
27. Validation of a risk prediction calculator in Australian patients undergoing head and neck microsurgery reconstruction
28. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre
29. Health-related quality of life in maxillectomy patients undergoing dentoalveolar rehabilitation
30. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
31. Quality of Life Outcomes in Patients Receiving Dental Implants in Vascularised Bone Flaps for Mandibular Reconstruction
32. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
33. Functional and aesthetic outcomes of dermofat graft reconstruction in limited parotidectomy defects: a cross-sectional study
34. Histological regression in melanoma: impact on sentinel lymph node status and survival
35. Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
36. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck
37. Validation of the American Joint Committee on Cancer Staging in Squamous Cell Carcinoma of the Vermilion Lip
38. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
39. ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases
40. ASO Visual Abstract: Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma
41. Management of the Parotid/Neck Following a Positive Sentinel Node Biopsy in Patients with Cutaneous Melanoma of the Head and Neck
42. Time and cost-analysis of virtual surgical planning for head and neck reconstruction: A matched pair analysis
43. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
44. Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe
45. ASO Visual Abstract: Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck
46. ASO Author Reflections: Surgery for pT3 and pT4 Cutaneous Squamous Cell Carcinomas of the Head and Neck Provides Robust Outcomes Against Which Emerging Treatment Modalities Should be Compared to Determine Their Role in the Standard of Care
47. Regional Metastasis in Head and Neck Cutaneous Squamous Cell Carcinoma: An Update on the Significance of Extra-Nodal Extension and Soft Tissue Metastasis
48. Sentinel Node Biopsy in 105 High-Risk Cutaneous SCCs of the Head and Neck: Results of a Multicenter Prospective Study
49. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
50. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.